Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world "comparative ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...